MM Curator summary
[ MM Curator Summary]: Oregon is hoping to be subject to extreme drug costs.
The article below has been highlighted and summarized by our research team. It is provided here for member convenience as part of our Curator service.
WASHINGTON — Oregon is gearing up to ask the Biden administration if its Medicaid program can avoid paying for drugs approved through a fast-track approval pathway — like Biogen’s pricey, controversial new Alzheimer’s drug, Aduhelm.
Oregon announced this month it is planning to formally submit a request to the administration to let its state out of a law that requires Medicaid programs to cover nearly all Food and Drug Administration-approved drugs.